Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T03403
|
||||
Former ID |
TTDS00039
|
||||
Target Name |
Cyclooxygenase
|
||||
Synonyms |
Cyclooxygenase (COX1 and COX2); PHS; Prostaglandin H2 synthase; Prostaglandin synthase
|
||||
Target Type |
Successful
|
||||
Disease | Ankylosing spondylitis [ICD9: 720; ICD10: M08.1, M45] | ||||
Asthma [ICD10: J45] | |||||
Atopic dermatitis [ICD9: 691.8, 692.9; ICD10: L00-L99] | |||||
Arthritis [ICD9: 710-719; ICD10: M00-M25] | |||||
Back pain [ICD9: 724.5,338,780; ICD10: M54, G89, R52] | |||||
Cerebrovascular ischaemia [ICD9: 434.91; ICD10: I61-I63] | |||||
Cardiovascular disorder [ICD10: I00-I99] | |||||
Chemotherapy or radiotherapy-induced mucositis [ICD9: 338, 528.0,780; ICD10: K12.3, R52, G89] | |||||
Dysmenorrhea [ICD9: 625.3; ICD10: N94.4-N94.6] | |||||
Hyperglyceridemic [ICD9: 790.29; ICD10: R73.9] | |||||
Inflammatory disease [ICD9: 140-229, 147, 173, 573.3, 710-719; ICD10: C11, C44, K75.9, M00-M25] | |||||
Immuno-modulator [ICD9: 135, 691.8, 692.9, 710-719, 714; ICD10: D86, L20, L20-L30, M00-M25, M05-M06] | |||||
Inflammation [ICD10: E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89] | |||||
Inflammatory bowel disease [ICD9: 555, 556; ICD10: K50, K51] | |||||
Joint and muscular pain; Ankylosing spondylitis [ICD9:719.4, 729.1, 338, 780, 720; ICD10: M25.5, M79.1, G89, R52, M08.1, M45] | |||||
Migraine [ICD9: 346; ICD10: G43] | |||||
Myocardial infarction; Cerebrovascular ischaemia [ICD9: 410, 434.91; ICD10: I21, I22, I61-I63] | |||||
Osteoarthritis of knee [ICD10: M15-M19, M47] | |||||
Osteoarthritis [ICD9: 715; ICD10: M15-M19, M47] | |||||
Otitis media [ICD10: H65-H67] | |||||
Parkinson's disease [ICD9: 332; ICD10: G20] | |||||
Pain [ICD9: 338, 356.0, 356.8,780; ICD10: G64, G90.0, R52, G89] | |||||
Postoperative inflammation undergone cataract extraction [ICD code not available] | |||||
Platelet aggregatory [ICD10: D69.1] | |||||
Rheumatoid arthritis [ICD9: 710-719, 714; ICD10: M05-M06] | |||||
Type 2 diabetes; Early nephropathy; Claudication [ICD9: 250, 250.00, 250.02, 250.4, 338, 437.6, 443.9, 453, 580-599, 671.5, 671.9,780; ICD10: E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89] | |||||
Unspecified [ICD code not available] | |||||
BioChemical Class |
Oxidoreductases acting on paired donors
|
||||
Target Validation |
T03403
|
||||
Drugs and Mode of Action | |||||
Drug(s) | Aceclofenac | Drug Info | Approved | Inflammatory disease | [524388], [551871] |
Acetaminophen | Drug Info | Approved | Pain | [538502], [540707] | |
Ampiroxicam | Drug Info | Approved | Inflammatory disease | [551871] | |
Amtolmetin guacil | Drug Info | Approved | Inflammatory disease | [551871] | |
Asasantin | Drug Info | Approved | Cerebrovascular ischaemia | [536186] | |
Aspirin | Drug Info | Approved | Pain | [467484], [536186] | |
Dexibuprofen | Drug Info | Approved | Ankylosing spondylitis | [551871] | |
Diclofenac | Drug Info | Approved | Osteoarthritis of knee | [551871] | |
Felbinac | Drug Info | Approved | Arthritis | [551871] | |
Fenoprofen | Drug Info | Approved | Rheumatoid arthritis | [468052], [538244] | |
Fosfosal | Drug Info | Approved | Pain | [551871] | |
Icosapent | Drug Info | Approved | Hyperglyceridemic | [542465], [550112] | |
Ketorolac | Drug Info | Approved | Postoperative inflammation undergone cataract extraction | [551871] | |
Lornoxicam | Drug Info | Approved | Migraine | [522825], [551871] | |
Loxoprofen gel | Drug Info | Approved | Inflammatory disease | [522818], [551871] | |
Meclofenamic acid | Drug Info | Approved | Joint and muscular pain; Ankylosing spondylitis | [536575], [542233], [551871] | |
Morniflumate | Drug Info | Approved | Otitis media | [551871] | |
Nepafenac | Drug Info | Approved | Osteoarthritis | [542564], [551186], [551871] | |
Oxaprozin | Drug Info | Approved | Rheumatoid arthritis | [551871] | |
Pelubiprofen | Drug Info | Approved | Back pain | [551871] | |
Pravigard | Drug Info | Approved | Myocardial infarction; Cerebrovascular ischaemia | [536186] | |
Aspirin | Drug Info | Phase 3 | Cardiovascular disorder | [467484], [526874], [533508] | |
K-103-IP | Drug Info | Phase 3 | Pain | [524680] | |
Naproxcinod | Drug Info | Phase 3 | Inflammatory disease | [522137] | |
BN82451 | Drug Info | Phase 2 | Parkinson's disease | [524900] | |
NCX 1022 | Drug Info | Phase 2 | Atopic dermatitis | [551443] | |
NCX-4016 | Drug Info | Phase 2 | Inflammation | [527729] | |
TZI-41078 | Drug Info | Phase 2 | Arthritis | [534101] | |
4-aminosalicylate sodium (oral controlled release, ulcerative colitis), AGI Therapeutics | Drug Info | Phase 1 | Inflammatory bowel disease | [548169] | |
SKF-105809 | Drug Info | Phase 1 | Pain | [529852] | |
Felbinac prodrug | Drug Info | Preclinical | Inflammatory disease | [546514] | |
Droxicam | Drug Info | Withdrawn from market | Inflammatory disease | [545401] | |
Zomepirac | Drug Info | Withdrawn from market | Pain | [551871] | |
Bermoprofen | Drug Info | Discontinued in Preregistration | Inflammatory disease | [544769] | |
Pirazolac | Drug Info | Discontinued in Preregistration | Inflammatory disease | [544777] | |
KC-764 | Drug Info | Discontinued in Phase 3 | Platelet aggregatory | [544800] | |
Benzydamine | Drug Info | Discontinued in Phase 2 | Chemotherapy or radiotherapy-induced mucositis | [536838] | |
D-7193 | Drug Info | Discontinued in Phase 2 | Immuno-modulator | [546273] | |
FS-205-397 | Drug Info | Discontinued in Phase 2 | Pain | [545598] | |
NCX-4016 | Drug Info | Discontinued in Phase 2 | Type 2 diabetes; Early nephropathy; Claudication | [536186] | |
NCX-701 | Drug Info | Discontinued in Phase 2 | Pain | [547214] | |
PSD-508 | Drug Info | Discontinued in Phase 2 | Dysmenorrhea | [548659] | |
D-1367 | Drug Info | Discontinued in Phase 1 | Arthritis | [546016] | |
Eltenac | Drug Info | Discontinued in Phase 1 | Arthritis | [545584] | |
F-11105 | Drug Info | Discontinued in Phase 1 | Asthma | [546838] | |
E-5110 | Drug Info | Terminated | Inflammatory disease | [544773] | |
Florifenine | Drug Info | Terminated | Inflammatory disease | [545593] | |
NMI-1182 | Drug Info | Terminated | Inflammatory disease | [547873] | |
RP-66364 | Drug Info | Terminated | Inflammatory disease | [545586] | |
S-14080 | Drug Info | Terminated | Inflammatory disease | [533782] | |
WY-28342 | Drug Info | Terminated | Rheumatoid arthritis | [545972] | |
Diclofenac | Drug Info | Investigative | Unspecified | [525985], [551871] | |
Modulator | 4-aminosalicylate sodium (oral controlled release, ulcerative colitis), AGI Therapeutics | Drug Info | [531873] | ||
Aceclofenac | Drug Info | [526718], [551871] | |||
Ampiroxicam | Drug Info | [528085], [551871] | |||
Amtolmetin guacil | Drug Info | [527959], [551871] | |||
Bermoprofen | Drug Info | [529154] | |||
D-1367 | Drug Info | [550835] | |||
D-7193 | Drug Info | [550919] | |||
Dexibuprofen | Drug Info | [526606], [551871] | |||
Diclofenac | Drug Info | [525985], [551871] | |||
Droxicam | Drug Info | [526788] | |||
E-5110 | Drug Info | [533847] | |||
Eltenac | Drug Info | [525975] | |||
Felbinac | Drug Info | [533532], [551871] | |||
Felbinac prodrug | Drug Info | [550035], [551871] | |||
Florifenine | Drug Info | [533656] | |||
Fosfosal | Drug Info | [533530], [536361] | |||
FS-205-397 | Drug Info | [533438], [551871] | |||
K-103-IP | Drug Info | [524680] | |||
KC-764 | Drug Info | [527720], [551871] | |||
Lornoxicam | Drug Info | [525560], [551871] | |||
Morniflumate | Drug Info | [528117], [551871] | |||
Naproxcinod | Drug Info | [537263] | |||
NCX 1022 | Drug Info | [527171] | |||
NCX-701 | Drug Info | [529064], [544102] | |||
Pelubiprofen | Drug Info | [531590], [551871] | |||
Pirazolac | Drug Info | [533491] | |||
RP-66364 | Drug Info | [550934] | |||
S-14080 | Drug Info | [550923] | |||
SKF-105809 | Drug Info | [529852] | |||
TZI-41078 | Drug Info | [534101], [551871] | |||
WY-28342 | Drug Info | [533715] | |||
Zomepirac | Drug Info | [533421], [551871] | |||
Inhibitor | Acetaminophen | Drug Info | [535569], [535717], [536038] | ||
Asasantin | Drug Info | [536186] | |||
Aspirin | Drug Info | [536976] | |||
Benzydamine | Drug Info | [536838] | |||
BN82451 | Drug Info | [537349] | |||
F-11105 | Drug Info | [550919] | |||
Fenoprofen | Drug Info | [536364], [536391] | |||
Ketorolac | Drug Info | [536379] | |||
Loxoprofen gel | Drug Info | [532557], [551871] | |||
Meclofenamic acid | Drug Info | [537872], [537903] | |||
NCX-4016 | Drug Info | [536186] | |||
Nepafenac | Drug Info | [526496], [551871] | |||
NMI-1182 | Drug Info | [527835] | |||
Oxaprozin | Drug Info | [536391] | |||
Pravigard | Drug Info | [536186] | |||
PSD-508 | Drug Info | [550869] | |||
Binder | Icosapent | Drug Info | [535691] | ||
References | |||||
Ref 467484 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4139). | ||||
Ref 468052 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4820). | ||||
Ref 522137 | ClinicalTrials.gov (NCT00541489) Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Hip. U.S. National Institutes of Health. | ||||
Ref 522818 | ClinicalTrials.gov (NCT00994461) Study Of Celecoxib In Healthy Subjects. U.S. National Institutes of Health. | ||||
Ref 522825 | ClinicalTrials.gov (NCT00997750) Efficacy and Safety of Lornoxicam in Patients With Acute Coronary Syndrome. U.S. National Institutes of Health. | ||||
Ref 524388 | ClinicalTrials.gov (NCT01912066) A Multicenter, Double Blinded, Randomized, Parallel Assignment Study to Demonstrate the Efficacy of DA9601. U.S. National Institutes of Health. | ||||
Ref 524680 | ClinicalTrials.gov (NCT02089425) An Efficacy and Safety Study for the Treatment of Mild to Moderate Acute Pain Associated With Ankle Strain or Sprain.. U.S. National Institutes of Health. | ||||
Ref 524900 | ClinicalTrials.gov (NCT02231580) Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients. U.S. National Institutes of Health. | ||||
Ref 525985 | Diclofenac and NS-398, a selective cyclooxygenase-2 inhibitor, decrease agonist-induced contractions of the pig isolated ureter. Urol Res. 2000 Dec;28(6):376-82. | ||||
Ref 527729 | Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016). J Pharmacol Exp Ther. 2005 Dec;315(3):1331-7. Epub 2005 Sep 6. | ||||
Ref 529852 | Analgetic activity of SK&F 105809, a dual inhibitor of arachidonic acid metabolism. Agents Actions Suppl. 1991;32:113-7. | ||||
Ref 533508 | Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232-5. | ||||
Ref 533782 | S14080, a peripheral analgesic acting by release of an endogenous circulating opioid-like substance. Br J Pharmacol. 1995 Jan;114(2):303-8. | ||||
Ref 534101 | Hydroxylamine analogs of 2,6-di-t-butylphenols: dual inhibitors of cyclooxygenase and 5-lipoxygenase or selective 5-lipoxygenase inhibitors. Bioorg Med Chem. 1995 Apr;3(4):403-10. | ||||
Ref 536186 | Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. | ||||
Ref 536575 | Pharmacology, pharmacokinetics, and therapeutic use of meclofenamate sodium. Clin J Pain. 1991;7 Suppl 1:S44-8. | ||||
Ref 536838 | Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs. 2008 Sep;13(3):511-22. | ||||
Ref 538244 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 072267. | ||||
Ref 538502 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 018337. | ||||
Ref 540707 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5239). | ||||
Ref 542233 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7219). | ||||
Ref 542465 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7441). | ||||
Ref 542564 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7564). | ||||
Ref 544769 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000932) | ||||
Ref 544773 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000953) | ||||
Ref 544777 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000980) | ||||
Ref 544800 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001148) | ||||
Ref 545401 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003115) | ||||
Ref 545584 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003785) | ||||
Ref 545586 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003795) | ||||
Ref 545593 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003826) | ||||
Ref 545598 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003851) | ||||
Ref 545972 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005582) | ||||
Ref 546016 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005889) | ||||
Ref 546273 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007192) | ||||
Ref 546514 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008689) | ||||
Ref 546838 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010557) | ||||
Ref 547214 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014096) | ||||
Ref 547873 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020060) | ||||
Ref 548169 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022712) | ||||
Ref 524680 | ClinicalTrials.gov (NCT02089425) An Efficacy and Safety Study for the Treatment of Mild to Moderate Acute Pain Associated With Ankle Strain or Sprain.. U.S. National Institutes of Health. | ||||
Ref 525560 | The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79. | ||||
Ref 525975 | Effect of eltenac in horses with induced endotoxaemia. Equine Vet J Suppl. 2000 Jun;(32):26-31. | ||||
Ref 525985 | Diclofenac and NS-398, a selective cyclooxygenase-2 inhibitor, decrease agonist-induced contractions of the pig isolated ureter. Urol Res. 2000 Dec;28(6):376-82. | ||||
Ref 526496 | Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci. 2003 Jan;44(1):409-15. | ||||
Ref 526606 | Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip. Int J Clin Pharmacol Ther. 2003 Apr;41(4):153-64. | ||||
Ref 526718 | Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther. 2003 Sep;74(3):222-35. | ||||
Ref 527171 | Anti-inflammatory effects of nitric oxide-releasing hydrocortisone NCX 1022, in a murine model of contact dermatitis. Br J Pharmacol. 2004 Nov;143(5):618-25. Epub 2004 Aug 16. | ||||
Ref 527720 | Clinical and preclinical pharmacology of KC-764, a novel antiplatelet agent. Nihon Rinsho. 1992 Feb;50(2):379-84. | ||||
Ref 527835 | NMI-1182, a gastro-protective cyclo-oxygenase-inhibiting nitric oxide donor. Inflammopharmacology. 2005;12(5-6):521-34. | ||||
Ref 527959 | Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2005 Nov-Dec;23(6):809-18. | ||||
Ref 528085 | Premedication with cyclooxygenase-2 inhibitor meloxicam reduced postoperative pain in patients after oral surgery. Int J Oral Maxillofac Surg. 2006 Jul;35(7):613-7. Epub 2006 Mar 15. | ||||
Ref 528117 | Modulation of arachidonic acid metabolism by orally administered morniflumate in man. Agents Actions. 1991 Jul;33(3-4):233-9. | ||||
Ref 529064 | Nitroparacetamol (NCX-701) and pain: first in a series of novel analgesics. CNS Drug Rev. 2007 Fall;13(3):279-95. | ||||
Ref 529154 | Prolongation of antipyretic action and reduction of gastric ulcerogenicity in the rat by controlled-release granules of bermoprofen, a new nonsteroidal anti-inflammatory drug. J Pharm Sci. 1991 Sep;80(9):876-80. | ||||
Ref 529852 | Analgetic activity of SK&F 105809, a dual inhibitor of arachidonic acid metabolism. Agents Actions Suppl. 1991;32:113-7. | ||||
Ref 531590 | Anti-inflammatory effect of pelubiprofen, 2-[4-(oxocyclohexylidenemethyl)-phenyl]propionic acid, mediated by dual suppression of COX activity and LPS-induced inflammatory gene expression via NF-?B inactivation. J Cell Biochem. 2011 Dec;112(12):3594-603. | ||||
Ref 531873 | 5-aminosalicylic acid mediates expression of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase to suppress colorectal tumorigenesis. Anticancer Res. 2012 Apr;32(4):1193-202. | ||||
Ref 532557 | Comparative study of the clinical efficacy of the selective cyclooxygenase-2 inhibitor celecoxib compared with loxoprofen in patients with frozen shoulder. Mod Rheumatol. 2014 Jan;24(1):144-9. | ||||
Ref 533421 | Effect of preischemia cyclooxygenase inhibition by zomepirac sodium on reflow, cerebral autoregulation, and EEG recovery in the cat after global ischemia. J Cereb Blood Flow Metab. 1986 Dec;6(6):691-702. | ||||
Ref 533438 | FS 205-397: a new antipyretic analgesic with a paracetamol-like profile of activity but lack of acute hepatotoxicity in mice. Life Sci. 1988;43(11):905-12. | ||||
Ref 533491 | Differential dosing study of pirazolac, a new non-steroidal anti-inflammatory agent, in patients with rheumatoid arthritis. Curr Med Res Opin. 1985;9(8):542-7. | ||||
Ref 533530 | Pharmacological study of 2-phosphonoxybenzoic acid (fosfosal), a new analgesic drug. Arzneimittelforschung. 1980;30(7):1091-8. | ||||
Ref 533532 | A review of the effects of fenbufen and a metabolite, biphenylacetic acid, on platelet biochemistry and function. Arzneimittelforschung. 1980;30(4A):702-7. | ||||
Ref 533656 | A study of the novel anti-inflammatory agent florifenine topical anti-inflammatory activity and influence on arachidonic acid metabolism and neutrophil functions. Naunyn Schmiedebergs Arch Pharmacol.1995 Mar;351(3):298-304. | ||||
Ref 533715 | Synthesis and antiinflammatory activity of certain 5,6,7,8-tetrahydroquinolines and related compounds. J Med Chem. 1995 Apr 28;38(9):1473-81. | ||||
Ref 533847 | Effect of E-5110, a novel non-steroidal anti-inflammatory drug, on trimethadione metabolism as an indicator of hepatic drug-oxidizing capacity in beagle dog. Xenobiotica. 1994 Mar;24(3):215-20. | ||||
Ref 534101 | Hydroxylamine analogs of 2,6-di-t-butylphenols: dual inhibitors of cyclooxygenase and 5-lipoxygenase or selective 5-lipoxygenase inhibitors. Bioorg Med Chem. 1995 Apr;3(4):403-10. | ||||
Ref 535569 | COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13926-31. Epub 2002 Sep 19. | ||||
Ref 535691 | Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res. 2003 Mar;44(3):479-86. Epub 2002 Dec 1. | ||||
Ref 535717 | COX-3: just another COX or the solitary elusive target of paracetamol? Lancet. 2003 Mar 22;361(9362):981-2. | ||||
Ref 536186 | Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. | ||||
Ref 536361 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
Ref 536364 | Immunomodulatory effect of nonsteroidal anti-inflammatory drugs (NSAIDs) at the clinically available doses. Arch Pharm Res. 2007 Jan;30(1):64-74. | ||||
Ref 536379 | Cyclooxygenase and nitric oxide synthase dependence of cutaneous reactive hyperemia in humans. Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H425-32. Epub 2007 Mar 16. | ||||
Ref 536391 | The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007 Apr 1;67(7):3254-62. | ||||
Ref 536838 | Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs. 2008 Sep;13(3):511-22. | ||||
Ref 536976 | Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis. Cardiovasc Hematol Disord Drug Targets. 2008 Dec;8(4):268-77. | ||||
Ref 537263 | Naproxcinod, a new cyclooxygenase-inhibiting nitric oxide donator (CINOD). Expert Opin Biol Ther. 2009 May;9(5):649-57. | ||||
Ref 537349 | Emerging drug therapies in Huntington's disease. Expert Opin Emerg Drugs. 2009 Jun;14(2):273-97. | ||||
Ref 537872 | Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann N Y Acad Sci. 1994 Nov 15;744:50-7. | ||||
Ref 537903 | Pharmacology of prostaglandin endoperoxide synthase isozymes-1 and -2. Ann N Y Acad Sci. 1994 Apr 18;714:136-42. | ||||
Ref 544102 | Antinociceptive effects of NCX-701 (nitro-paracetamol) in neuropathic rats: enhancement of antinociception by co-administration with gabapentin. Br J Pharmacol. 2009 September; 158(2): 601-609. | ||||
Ref 550035 | Predicting Cyclooxygenase Inhibition by Three??imensional Pharmacophoric Profiling. Part I: Model Generation, Validation and Applicability in Ethnopharmacology. Molecular Informatics 01/2010; 29(1??):75 - 86. | ||||
Ref 550835 | US patent application no. 2007,0072,861, Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders. | ||||
Ref 550869 | CN patent application no. 104797935, A method for prognosis and treatment of cancer metastasis. | ||||
Ref 550923 | US patent application no. 7,022,689, 5-amidino-n-(2-aminophenethyl)-n-hydroxy-benzenesulffonamide derivative, medical composition containing the same, pharmaceutical use thereof and intermediate therefor. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.